Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Sionna Therapeutics Q3 EPS $(0.72) Misses $(0.62) Estimate
Sionna Therapeutics: The Market May Be Wrong About The Science, But Right About The Stock
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program - Slideshow
Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall
Sionna's SION-719 Failure Changes Everything (Rating Downgrade)
Sionna Therapeutics stock falls 92% after SION-719 trial failure
Guggenheim Downgrades Sionna Therapeutics to Neutral
Wedbush Downgrades Sionna Therapeutics to Neutral, Lowers Price Target to $5
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.